Document Detail

Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
MedLine Citation:
PMID:  20707758     Owner:  NLM     Status:  MEDLINE    
IMPORTANCE OF THE FIELD: Cardiovascular disease is a major cause of premature death and disability worldwide, and effective blood pressure (BP) control is crucial for the reduction of cardiovascular risk in patients with hypertension. Despite this, many will fail to attain recommended BP goals. A reappraisal of European guidelines led to revised recommendations for BP reduction to values within the SBP/DBP range of 130 - 139/80 - 85 mmHg in all patients with hypertension, including higher-risk groups such as those with diabetes.
AREAS COVERED IN THIS REVIEW: The majority of hypertensive patients will require the enhanced blood-pressure-lowering effects of at least two antihypertensive drugs with complementary mechanisms of action to achieve these goals.
WHAT THE READER WILL GAIN: The angiotensin II receptor blocker (ARB) olmesartan medoxomil and the thiazide diuretic hydrochlorothiazide (HCTZ) provide greater antihypertensive efficacy when used in combination than as monotherapy with either component, with a similar tolerability profile. In addition, there is evidence that higher doses of olmesartan may prolong the antihypertensive effect of this ARB, and a number of US 'treat-to-target' and European add-on clinical trials have been conducted to assess the efficacy and safety of high-dose olmesartan plus HCTZ in a wide range of patients with mild-to-severe hypertension.
TAKE HOME MESSAGE: Combination therapy with olmesartan, including the high 40-mg dose, plus HCTZ is an effective and safe treatment option for controlling BP in patients with mild-to-severe hypertension, particularly those who fail to achieve recommended BP goals with monotherapy.
Lars Christian Rump; Lorenz Sellin
Related Documents :
8448068 - Evening vs morning isradipine sustained release in essential hypertension: a double-bli...
12089368 - Cardiac and renal effects of standard versus rigorous blood pressure control in autosom...
19821398 - Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypert...
12933418 - Patients with severe preeclampsia experience less hypotension during spinal anesthesia ...
2330978 - Effect of dopamine on the tubuloglomerular feedback mechanism.
16127308 - Excessive hypertension and pulmonary edema after electroconvulsive therapy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  11     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-16     Completed Date:  2011-01-31     Revised Date:  2013-08-15    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2231-42     Citation Subset:  IM    
Department of Internal Medicine/Nephrology, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / adverse effects,  pharmacology,  therapeutic use*
Antihypertensive Agents / adverse effects,  pharmacology,  therapeutic use*
Dose-Response Relationship, Drug
Drug Therapy, Combination
Hydrochlorothiazide / adverse effects,  pharmacology,  therapeutic use*
Hypertension / drug therapy*
Imidazoles / adverse effects,  pharmacology,  therapeutic use*
Sodium Chloride Symporter Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Tetrazoles / adverse effects,  pharmacology,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Imidazoles; 0/Sodium Chloride Symporter Inhibitors; 0/Tetrazoles; 58-93-5/Hydrochlorothiazide; 6M97XTV3HD/olmesartan medoxomil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Next Document:  Ticagrelor for the treatment of arterial thrombosis.